SAFETY OF VENOMENHAL® VENOM IN MAINTENANCE HYMENOPTERA VENOM IMMUNOTHERAPY
Keywords:
allergen extracts, Hymenoptera venom allergy, immunotherapy, safetyAbstract
Background. Venomenhal® (V) is a new brand of
Hymenoptera venom allergen for diagnosis and immunotherapy
of venom allergy. We studied the safety of switching the
patients treated with other brands of venom to V.
Methods. We performed duplicate skin prick tests with V and
ALK Reless® (R) venom extract (100 μg/ml) in 68 patients (50
males, 42 ± 15 years) on maintenance immunotherapy with
honey bee (26) or wasp (42) venom. On two consecutive maintenance
injection days 53 patients received in random order
either 100 μg of R or V venom.
Results. Weal diameter in skin prick tests (mean ± st.dev.) were
3.9 ± 1.1 mm (V) and 4.1 ± 1.0 mm (R) for bee venom (NS)
and 3.4 ± 1.0 mm (V) and 3.9 ± 1.2 mm (R) for wasp venom (p
< 0.01). Local reaction 30 minutes after maintenance injection
were 6.1 ± 1.7 cm (V) and 5.4 ± 2.5 cm (R) for bee venom
(NS) and 5.1 ± 1.8 cm (V) and 6.1 ± 1.8 cm (R) for wasp venom
(p < 0.05).
Late local reactions (LLR) and tiredness (T) on the day of injection
and 24 hours after injection were equally distributed
among both groups and were mild (LLR on the day of injection:
38% of patients [V] vs. 43% [R]. LLR after 24 hours: 28%
[V] vs. 28% [R]. T on the day of injection: 21% [V] vs. 23% [R].
T after 24 hours: 0% [V] vs. 6% [R]).
Conclusions. V was at least as safe as A. There were no adverse
reactions due to switching from one brand to another. Slightly
but significantly smaller weal in skin prick tests and immediate
local reactions might be due to lesser potency or better
purification of V wasp extract.
Downloads
References
Allergy 1979; 9: 385–90.
2. Müller U, Mosbech H. Position paper: Immunotherapy with Hymenoptera
venoms. Allergy 1994; 48: Suppl 14: 36–46.
3. Birnbaum J, Charpin D, Vervioet D. Rapid Hymenoptera venoms immunotherapy:
Comparative safety of three protocols. Clin Exp Allergy 1992; 23:
226–30.
4. Hunt JK et al. A controlled trial of immunotherapy in insect hypersensitivity.
N Engl J Med 1978; 299: 157–61.
5. Youlten LJF, Atkinson BA, Lee TH. The incidence and nature of adverse
reactions to injection immunotherapy in bee and wasp venom allergy. Clin
Exp Allergy 1995; 25: 159–65.
6. Mosbech H, Müller U. Side effects of insect venom immunotherapy: Results
from an EAACI multicenter study. Allergy 2000; 55: 1005–10.
7. Dreborg S. Skin tests used in type I allergy testing. Position paper. Allergy
1989; 44: Suppl 10: 11–59.
8. Bousquet J. Allergen immunotherapy: therapeutic vaccines for allergic
diseases. WHO position paper. J Allergy Clin Immunol 1998; 102: 558–62.
9. Kochuyt AM, Stevens EAM. Safety and efficacy of a 12-week maintenance
interval in patients treated with Hymenoptera venom immunotherapy. Clin
Exp Allergy 1994; 24: 35–41.
Downloads
Published
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.